Showing results (371-380 of 400) with videos related to
Sort By:
Pageof 40
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 22, 2023
Clinical characteristics and outcomes of follicular lymphoma patients with extranodal involvement: analysis of a series of 1090 cases in ChinaZhijuan Lin, Jie Zha, Shuhua Yi, et al.Medcomm|June 19, 2023
Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T-cell lymphomaYali Wang, Wenbo Zhou, Jianfeng Chen, et al.Blood Advances|August 14, 2025
Phase 2 Study of Relmacabtagene Autoleucel (CD19 CAR-T) for Relapsed/Refractory Mantle Cell Lymphoma in Chinese AdultsYan Xie, Keshu Zhou, Lanfang Li, et al.Cancer Research and Treatment|October 5, 2018
Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 TrialXueying Li, He Huang, Bing Xu, et al.Journal of Hematology & Oncology|August 24, 2021
Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in ChinaJie Zha, Liyuan Fan, Shuhua Yi, et al.Blood Cancer Journal|March 18, 2026
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)Juying Wei, Qingqing Cai, Liling Zhang, et al.Signal Transduction and Targeted Therapy|May 16, 2024
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II studyYan Gao, Haixia He, Xueping Li, et al.Plos One|September 17, 2013
Downstream signaling pathways in mouse adipose tissues following acute in vivo administration of fibroblast growth factor 21Eric S Muise, Sandra Souza, An Chi, et al.Cancer Medicine|May 3, 2025
Chidamide, a Histone Deacetylase Inhibitor, Combined With R-GemOx in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (TRUST): A Multicenter, Single-Arm, Phase 2 TrialQihua Zou, Yuchen Zhang, Hui Zhou, et al.Oncogene|May 23, 2024
Targeting AURKA to induce synthetic lethality in CREBBP-deficient B-cell malignancies via attenuation of MYC expressionYichen Sun, Jianfeng Chen, Jing Han Hong, et al.Pageof 40